Related Experiment Video
Updated: Oct 29, 2025
Cecal Ligation Puncture Procedure
Published on: May 7, 2011
Cangrelor ameliorates CLP-induced pulmonary injury in sepsis by inhibiting GPR17
Qiancheng Luo1, Rui Liu2, Kaili Qu3
1Department of Critical Care Medicine, Shanghai Gongli Hospital, The Second Military Medical University, Shanghai, 200135, People's Republic of China.
Insights
Cangrelor treatment alleviates sepsis-induced lung injury by reducing inflammation and apoptosis. This study shows cangrelor represses G-protein-coupled receptor 17 (GPR17) levels, offering a potential therapeutic strategy for sepsis complications.
Area of Science:
- Biomedical research
- Pharmacology
- Immunology
Background:
- Sepsis, a life-threatening condition often arising from severe infections, carries a high mortality rate.
- Cangrelor, a P2Y12 receptor inhibitor, functions as an antagonist anti-platelet drug.
Purpose of the Study:
- To investigate the protective mechanisms of cangrelor in the context of sepsis-induced pulmonary injury.
- To evaluate cangrelor's effects on lung apoptosis, fibrosis, and inflammatory responses in a mouse model.
Main Methods:
- Utilized cecal ligation and puncture (CLP)-induced sepsis mouse models (C57BL/6).
- Assessed lung injury using TdT-mediated dUTP Nick-End Labeling (TUNEL) and Masson staining.
- Quantified neutrophils in bronchoalveolar lavage fluid (BALF).
- Measured inflammatory cytokine levels (IL-1β, IL-6, TNF-α) and G-protein-coupled receptor 17 (GPR17) expression via Western blotting and RT-PCR.
Main Results:
- Cangrelor treatment significantly reduced lung apoptosis and fibrosis.
- The drug promoted CD40L expression on platelets and inhibited neutrophil infiltration in BALF.
- Cangrelor decreased inflammatory cytokine levels (IL-1β, IL-6, TNF-α) and GPR17 expression.
- A significant reduction in GPR17 levels was observed post-cangrelor treatment (p < 0.001).
Conclusions:
- Cangrelor demonstrates protective effects against sepsis-induced pulmonary injury.
- The mechanism involves the repression of GPR17, leading to reduced inflammation and altered neutrophil presence in BALF.
- Cangrelor holds potential as a therapeutic agent for reversing CLP-mediated pulmonary damage in sepsis.
Background:
Sepsis is a common complication of severe wound injury and infection, with a very high mortality rate. The P2Y12 receptor inhibitor, cangrelor, is an antagonist anti-platelet drug.
Methods:
In our study, we investigated the protective mechanisms of cangrelor in CLP-induced pulmonary injury in sepsis, using C57BL/6 mouse models.
Results:
TdT-mediated dUTP Nick-End Labeling (TUNEL) and Masson staining showed that apoptosis and fibrosis in lungs were alleviated by cangrelor treatment. Cangrelor significantly promoted surface expression of CD40L on platelets and inhibited CLP-induced neutrophils in Bronchoalveolar lavage fluid (BALF) (p < 0.001). We also found that cangrelor decreased the inflammatory response in the CLP mouse model and inhibited the expression of inflammatory cytokines, IL-1β (p < 0.01), IL-6 (p < 0.05), and TNF-α (p < 0.001). Western blotting and RT-PCR showed that cangrelor inhibited the increased levels of G-protein-coupled receptor 17 (GPR17) induced by CLP (p < 0.001).
Conclusion:
Our study indicated that cangrelor repressed the levels of GPR17, followed by a decrease in the inflammatory response and a rise of neutrophils in BALF, potentially reversing CLP-mediated pulmonary injury during sepsis.
